The Board of Directors of Biosys UK Limited combines expertise across industry, academia, drug development and the investment community, unified by a mission to improve the lives of patients

Kai Joachimsen, MD, MBA: CEO and Director

Kai is the CEO of Biosys UK Limited with a strong background in the pharmaceutical Industry and healthcare industries.  Kai is a certified doctor., with MBA studies in Germany and the USA.  After his time in surgery, he held positions in leading pharmaceutical companies such as GSK, Boehringer Ingelheim, Merck Sharp and Dohme and Chiesi GmbH Germany.  Most recently he held the position of Group Chief Executive Officer at OmniaMed Holding.  Kai has an MD (University of Münster) and MBA (Kellogg School of Management).

Gunnar Weikert, MD, PhD, MBA: Non-executive Director

Gunnar is the Chairman and Founder of Inventages, one of the world’s largest specialised life science investors. He was previously a Senior VP at Bayer AG, and has more than 20 years experience in the life sciences industry.

Axel Wiest, MD, PhD, MPH: Non-executive Director

Axel is a senior executive with several years of experience in the biopharmaceutical and healthcare industries. He is currently SVP/COO R&D and Head of Global Strategy and Business Operations R&D at Merck Biopharma. Previously he held leadership roles at Boehringer Ingelheim Biopharmaceuticals and Fresenius. 

Matthew Edwards, BA, LLB: Non-executive Director

Matthew is General Counsel at Inventages. Prior to joining Inventages, Matthew was a Special Counsel at Covington & Burling LLP, advising clients on mergers and acquisitions, IPOs and other securities issues, as well as corporate finance and venture capital transactions, with a particular focus on the life sciences and technology sectors.